School of Veterinary Medicine

Yasushi Kataoka

  (片岡 康)

Profile Information

Affiliation
Faculty of Veterinary ScienceSchool of Veterinary Medicine, Nippon Veterinary and Life Science University

J-GLOBAL ID
201601018692277970
researchmap Member ID
B000267203

Papers

 38
  • Kazuki Kiuno, Takuya Kato, Hiroko Otsubo, Ryoko Kibe, Yasushi Kataoka, Shin-ichi Hayama
    Animals, 13(1) 21-21, Dec 21, 2022  
    Leptospirosis is a zoonosis that affects humans and animals worldwide. Raccoons (Procyon lotor), adopted in urban environments, may act as potential reservoirs of Leptospira. We investigated the prevalence of pathogenic Leptospira in the kidney and urine samples of raccoons living in Tokyo, as well as anti-leptospiral antibodies in their serum, and aimed to examine the factors that expose raccoons to Leptospira. Polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) were used to detect leptospiral DNA and anti-leptospiral antibodies, respectively. Thirty-six of 156 raccoons (23.1%) were positive by PCR, and 16 of 165 raccoons (9.7%) were positive by ELISA. The prevalence and seroprevalence rates differed depending on the raccoon dispersal period. We used univariable logistic regression to estimate the environmental factors associated with pathogenic Leptospira and anti-leptospiral antibodies in raccoons. Significant differences were observed in the PCR results for the seasons (spring–summer) (p = 0.01), average monthly temperature (p < 0.01), and average monthly rainfall (p < 0.01). No significant difference was seen in the ELISA results, but raccoons in larger urban areas tended to have higher seroprevalence rates (p = 0.06). We identified a pattern of leptospiral spread in raccoon dispersal and environmental factors that expose raccoons to Leptospira.
  • Mieko SUGIYAMA, Masako WATANABE, Takahisa SONOBE, Ryoko KIBE, Shuichi KOYAMA, Yasushi KATAOKA
    Journal of Veterinary Medical Science, 84(7) 1023-1028, Jul, 2022  Peer-reviewedLast author
    The purpose of this retrospective study was to assess the efficacy of antimicrobial therapy for bovine acute Klebsiella pneumoniae mastitis. We evaluated data from cattle in Ehime, Japan, with naturally occurring acute mastitis due to K. pneumoniae (n=208) or Escherichia coli (n=201). Survival was significantly shorter in cattle with acute K. pneumoniae mastitis (median, 76 days) compared with the disease caused by E. coli (median 464 days). In 2004-2008, because both species were highly susceptible to cefazolin, cases of K. pneumoniae and E. coli mastitis were treated solely with cefazolin, yielding clinical cure rates of 52.8% for K. pneumoniae and 86.0% for E. coli. However, since 2009, the efficacy of treatment of K. pneumoniae mastitis with cefazolin alone has decreased. When cefazolin administered on the first disease day led to clinical improvement, treatment with cefazolin was continued. However, when cefazolin administered on the first disease day failed to yield clinical improvement, the antibiotic was switched to a fluoroquinolone on the second day, resulting in cure rates of 76.7% for K. pneumoniae and 80.0% for E. coli. These findings suggest that, when the first-line drug (e.g., cefazolin) is ineffective, promptly changing to a second-line drug (e.g., a fluoroquinolone) increases the cure rate for bovine K. pneumoniae mastitis.
  • Ayaka Niina, Ryoko Kibe, Ryohei Suzuki, Yunosuke Yuchi, Takahiro Teshima, Hirotaka Matsumoto, Yasushi Kataoka, Hidekazu Koyama
    Bioscience of microbiota, food and health, 40(2) 98-104, 2021  Peer-reviewed
    In human medicine, fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection. It has also been tested as a treatment for multiple gastrointestinal diseases, including inflammatory bowel disease (IBD). However, only a few studies have focused on the changes in the microbiome following FMT for canine IBD. Here, we performed FMT in nine dogs with IBD using the fecal matter of healthy dogs and investigated the subsequent changes in the fecal microbiome and clinical signs. In three dogs, the fecal microbiome was examined by 16S rRNA sequencing. Fusobacteria were observed at a low proportion in dogs with IBD. However, the post-FMT microbiome became diverse and showed a significant increase in Fusobacteria proportion. Fusobacterium was detected in the nine dogs by quantitative polymerase chain reaction. The proportion of Fusobacterium in the post-FMT fecal microbiome was significantly increased (p<0.05). The changes in clinical signs (e.g., vomiting, diarrhea, and weight loss) were evaluated according to the canine inflammatory bowel disease activity index. The score of this index significantly decreased in all dogs (p<0.05) with improvements in clinical signs. These improvements were related to the changes in the proportion of microbes, particularly the increase in Fusobacterium. The dogs with IBD showed a lower proportion of Fusobacterium than healthy dogs. This suggests that a low proportion of Fusobacterium is a characteristic feature of canine IBD and that Fusobacterium is involved in this disease. The results of this study may help elucidate the pathogenesis of this disease and its association with Fusobacterium.
  • Kazuki Harada, Shieri Irie, Mamoru Ohnishi, Yasushi Kataoka
    Antibiotics (Basel, Switzerland), 9(4), Apr 21, 2020  Peer-reviewed
    Cefapirin (CEP) and cefalonium (CNM) are first-generation cephalosporins widely used to treat bovine mastitis caused by Gram-positive bacteria including staphylococci. However, disks for susceptibility testing of those drugs in causative bacteria are not available. This study evaluated the efficacy of 10 µg and 30 µg pilot disks of CEP (CEP10 and CEP30) and CNM (CNM10 and CNM30) against 130 Staphylococcusaureus isolates from bovine mastitis. Scattergrams of minimum inhibitory concentrations (MICs) and zone diameters (ZDs) illustrated significant correlations between the MICs and ZDs of CEP10 (r = -0.912), CEP30 (r = -0.933), CNM10 (r = -0.847), and CNM30 (r = -0.807). The analysis by Normalized Resistance Interpretation indicated that the epidemiolocal cut-off value (ECV) of MIC for both cefapirin and cefalonium is ≤ 0.5 µg/mL, and the ECV of ZD for CEP10, CEP30, CNM10, and CNM30 were ≥ 22 mm, ≥ 25 mm, ≥ 22 mm, and ≥ 29 mm, respectively. We believe that both 10 μg and 30 μg CEP and CNM susceptibility disks will be helpful for guiding the appropriate use of these antibiotics for bovine mastitis. Further studies toward the establishment of clinical breakpoint of CEP and CNM would be needed for their routine use.
  • Akihiro Mori, Ai Goto, Ryoko Kibe, Hitomi Oda, Yasushi Kataoka, Toshinori Sako
    The Journal of veterinary medical science, 81(12) 1783-1790, Dec 26, 2019  Peer-reviewed
    The effects of prescription diets on canine intestinal microbiota are unknown. In this study, we used next generation sequencing to investigate the impact of four commercially available prescription diet regimens on the fecal microbiome in six healthy dogs. The diet regimens used were as follows: weight-loss diet, low-fat diet, renal diet, and anallergenic diet. We found a significantly decreased proportion of phylum Actinobacteria with the weight-loss diet compared to the anallergenic diet. There were no significant differences in the proportion of phylum Bacteroidetes between the four diets. The proportion of phylum Firmicutes was significantly decreased with the weight-loss diet compared to the anallergenic diet. The proportion of phylum Fusobacteria was significantly increased with the weight-loss diet compared to the anallergenic diet. There were no significant differences in the proportion of phylum Proteobacteria after consumption of the four diets. We therefore demonstrated that commercial prescription diet influences the fecal microbiome in healthy dogs. These results might be useful when choosing a prescription diet for targeting a disease.

Misc.

 17
  • OKAMOTO CHIAKI, SHIMIZU TAKAE, AOKI HIROSHI, HARADA KAZUKI, KATAOKA YASUSHI, ONO FUMIKO, KADOHIRA MUTSUYO, TAKAI SHINJI
    獣医疫学雑誌, 18(1) (JA)38,(EN)39-39, Jul 20, 2014  
  • 片岡 康
    動物用抗菌剤研究会報, (35) 71-73, Nov, 2013  
  • Nattawooti Sthitmatee, Sureerat Numee, Efichi Kawamoto, Hiraku Sasaki, Kaoru Yamashita, Naovuki Takahashi, Yasushi Kataoka, Takuo Sawada
    VACCINE, 26(19) 2398-2407, May, 2008  
    The recombinant adhesive protein (rCp39) of Pasteurella multocida strain P-1059 (serovar A:3) was prepared and purified with a hybrid condition of affinity chromatography. The rCp39 was highly protective for chickens from fowl cholera by challenge-exposure with parental strain P-1059 or heterologous strain X-73 (serovar A:1) compared to various kind of vaccines. Sixteen groups of ten chickens each were subcutaneously inoculated twice with 100, 200 or 400 mu g proteins of rCp39, native Cp39, native outer membrane protein H (OmpH) or recombinant OmpH, or 100 mu g proteins of crude capsular extract (CCE) of strains P-1059 or X-73 at 2 weeks interval. Five chickens of each group were challenge-exposed with each strain 2 weeks after the second inoculation. As the results, 60-100% protections were demonstrated in the chickens against both strains. Fisher's exact test indicated no significant differences (P&lt;0.05) in vaccine types and dosages. ELISA and Western blot analysis indicated that the chicken anti-rCp39 sera reacted to whole-cell lysate of parental or heterologous strains. In conclusion, rCp39 is a cross-protective recombinant adhesive antigen of P multocida capsular serogroup A strains. Moreover, a hybrid condition of affinity chromatography was successfully demonstrated and protected the immunogenicity of recombinant protein. (C) 2008 Elsevier Ltd. All rights reserved.
  • 岩崎 利郎, 浅井 鉄夫, 内田 幸治, 片岡 康, 桑野 昭, 澤田 拓士, 中田 勝久, 深田 恒夫
    動物用抗菌剤研究会報 = Proceedings of the Japanese Society of Antimicrobials for Animals, 29 1-1, Mar 25, 2008  
  • ARAI KUMI, ASAI TETSUO, AOKI HIROSHI, OZAWA MASANAO, KATAOKA YASUSHI, SAWADA HIROSHI, SAMEJIMA TOSHIYA
    日本獣医学会学術集会講演要旨集, 144th 105-105, Aug 27, 2007  

Teaching Experience

 8

Research Projects

 3